Large-scale clinical trials demonstrated that SGLT2 inhibitors reduce the risk of kidney and heart disease in patients dealing with heart failure (HF), CKD, or type 2 diabetes at risk of atherosclerotic cardiovascular problems [9, 41]. This evidence concerns the gene SLC5A2 and hydrops fetalis.